Skip to content

Study · Case report or series · 1992

5 results

Octreotide: a potent new non-opiate analgesic for intrathecal infusion.

Penn RD, Paice JA, Kroin JS

Pain1 Apr 1992Cited by 79 (Europe PMC)

PMID1594275 (opens in a new tab)DOI10.1016/0304-3959(92)90182-b (opens in a new tab)PepBankPUB-01594275
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In cancer patients with pain unrelieved by oral opiates, pain scores decreased during intrathecal octreotide infusion.

    In plain wordsIn cancer patients, pain scores decreased during intrathecal octreotide infusion compared with prior scores.

    Peptide
    Octreotide
    Outcome
    DecreasePain scores
    Study

    n: not reported in source

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    5-20 micrograms/h · intrathecal infusion · 13 to 91 daysAs given in this study (human).

    Source sentences

    Summary
    During octreotide infusion, pain scores were lower while oral opiate usage was reduced.
    1 context sentence
    Summary · context
    On the basis of these findings cancer patients with pain unrelieved by oral opiates were treated for periods of 13 to 91 days with intrathecal octreotide 5-20 micrograms/h.
  2. 02HumanCase report or seriesEfficacy outcome

    In cancer patients with pain unrelieved by oral opiates, oral opiate use decreased during intrathecal octreotide infusion.

    In plain wordsIn cancer patients, oral opiate use decreased during intrathecal octreotide infusion compared with prior use.

    Peptide
    Octreotide
    Outcome
    DecreaseOral opiate use
    Study

    n: not reported in source

    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    5-20 micrograms/h · intrathecal infusion · 13 to 91 daysAs given in this study (human).

    Source sentences

    Summary
    During octreotide infusion, pain scores were lower while oral opiate usage was reduced.
    1 context sentence
    Summary · context
    On the basis of these findings cancer patients with pain unrelieved by oral opiates were treated for periods of 13 to 91 days with intrathecal octreotide 5-20 micrograms/h.
  3. 03HumanCase report or seriesSafety outcome

    In cancer patients, intrathecal octreotide produced no observed central side effects.

    In plain wordsIn cancer patients, investigators observed no central side effects during intrathecal octreotide treatment.

    Peptide
    Octreotide
    Outcome
    Not applicableCentral side effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    5-20 micrograms/h · intrathecal infusion · 13 to 91 daysAs given in this study (human).

    Source sentences

    Summary
    No central or systemic side effects of intrathecal administration were seen.
    1 context sentence
    Summary · context
    On the basis of these findings cancer patients with pain unrelieved by oral opiates were treated for periods of 13 to 91 days with intrathecal octreotide 5-20 micrograms/h.
  4. 04HumanCase report or seriesSafety outcome

    In cancer patients, intrathecal octreotide produced no observed systemic side effects.

    In plain wordsIn cancer patients, investigators observed no systemic side effects during intrathecal octreotide treatment.

    Peptide
    Octreotide
    Outcome
    Not applicableSystemic side effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    5-20 micrograms/h · intrathecal infusion · 13 to 91 daysAs given in this study (human).

    Source sentences

    Summary
    No central or systemic side effects of intrathecal administration were seen.
    1 context sentence
    Summary · context
    On the basis of these findings cancer patients with pain unrelieved by oral opiates were treated for periods of 13 to 91 days with intrathecal octreotide 5-20 micrograms/h.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In dogs, chronic intrathecal and intraventricular octreotide perfusion at 40 micrograms/h did not produce neurotoxicity.

    In plain wordsIn dogs, chronic octreotide perfusion into spinal and brain fluid spaces did not produce neurotoxicity.

    Peptide
    Octreotide
    Outcome
    Not applicableNeurotoxicity in dogs
    Study

    dogn: not reported in source

    Chronic intrathecal and intraventricular perfusion
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    40 micrograms/h · intrathecal and intraventricular perfusionAs given in this study (dog).

    Source sentences

    Summary
    In preclinical trials in dogs, chronic intrathecal and intraventricular perfusion at 40 micrograms/h did not produce neurotoxicity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.